eligibility_summary
Adults (≥18) with ECOG 0–2 and histologically confirmed high‑grade serous epithelial ovarian, fallopian tube, or peritoneal cancer, recurrent platinum‑resistant/refractory (progression on platinum or relapse <6 months, CA‑125 rise alone not enough), ≥2 prior regimens. Requires consent/HIPAA and biopsies pre‑treatment, post‑infusion, and at progression. Exclude if unable/unwilling to comply or undergo biopsies, or if other malignancy could confound safety/efficacy.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Interventions: iC9-CAR.B7-H3 autologous CAR-T cells (gene-modified cellular immunotherapy) infused intraperitoneally, lymphodepleting cyclophosphamide (alkylating chemotherapy) and fludarabine (purine-analog antimetabolite). Mechanisms: CAR-T cells express a chimeric receptor that binds B7-H3 (CD276), activating T-cell cytotoxicity against B7-H3–positive ovarian cancer cells, product includes an inducible caspase-9 (iC9) safety switch that can be triggered by rimiducid to ablate CAR-T cells if severe toxicity occurs. Cells/pathways targeted: B7-H3/CD276 on tumor and tumor vasculature, T-cell effector pathways (perforin/granzyme, cytokines) for tumor killing, lymphodepletion diminishes host lymphocytes to promote CAR-T expansion. Population: recurrent platinum-resistant epithelial ovarian cancer.